The TTM operating margin for the company stands at 0%.
Synaptics Incorporated (NASDAQ:SYNA) exchanged hands 1,487,227 shares versus average trading capacity of 951.14K shares, while its relative trading volume is 1.56. Unusual volume shows something has likely happened in the stock-such as a news release or traders have become anxious or euphoric about the stock's potential.
Dugout more deeply and finding that are RPRX earnings expected to grow/drop in the future, for this we can take help from price to earnings growth ratio but it's unclear, it is determining a stock's value while taking into account the earnings' growth. Many investors will use the CCI in conjunction with other indicators when evaluating a trade.
Repros Therapeutics Inc. (RPRX) is recuperating from the fall at $0.26, the 52-week low. The Company's total market worth is $108.69B along with 1.36B outstanding shares.
While looking at the Stock's Performance, Repros Therapeutics Inc. now shows a Weekly Performance of 113.7%, where Monthly Performance is 120.41%, Quarterly performance is 14.76%, 6 Months performance is -35.11% and yearly performance percentage is -67.25%. (RPRX) has been moved; whether it performed well or not. APA share have plunged by -33.1% in percentage terms since the start of the year - and added 6.79% in the last month. However, 149.58% over the last one month, 35.33% for the last quarter and year to date performance stands at -43.18%.
FT reports, On Aug 14, 2017, Repros Therapeutics Inc reported 2nd quarter 2017 losses of -0.08 per share. (NASDAQ:RPRX) traded up 41.51% in the last session while performance was up 0.75% in the last five days. RPRX's latest closing price was -4.28% away from the average price of 200 days while it maintained a distance of 135.77% from the 50 Day Moving Average and 129.20% away compared to its SMA 20. The company has Relative Strength Index (RSI 14) of 89.42 along with Average True Range (ATR 14) of 0.08.
The stock has Return on Assets (ROA) of -212.1 percent. Repros Therapeutics had a negative net margin of 39,128.00% and a negative return on equity of 151.63%. A high ROE indicates successfully earning more assets and value for its shareholders off its reinvested earnings.
The company P/E (price to earnings) ratio is 0 and Forward P/E ratio is 0. It seems that Repros Therapeutics Inc. Share performance for the month is now at 76.49%. Regardless of which metric you utilize, a firm understanding of the concept of volatility and how it is measured is essential to successful investing. Company shares have been seen trading -66.05% off of the 52 week high and 184.65% away from the 52 week low. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market.
Higher-beta stocks tend to be more volatile and therefore riskier, but provide the potential for higher returns. For this reason, many traders with a high risk tolerance look to multiple measures of volatility to help inform their trade strategies. Recently, analysts have updated the overall rating to 2. It last reported revenues of $10000 and EPSfor the June 2017, representing 0% top-line growth and Last 4 Weeks EPS growth. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.